Market research
AERI Aerie Pharmace
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 754M
- P/E ratio
- Not available
- Analyst target
- 15.35
- Dividend yield
- 0.0%
- Beta
- -0.06
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- US00771V1089
- Market cap
- 754M
- P/E ratio
- Not available
- Analyst target
- 15.35
- Dividend yield
- 0.0%
- Beta
- -0.06
About
About Aerie Pharmace
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AERI discussion.
5 years, 4 months ago
Aerie Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 0.3% above its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.8.
Aerie Pharmaceuticals, Inc's total revenue rose by 0.1% to $25M since the same quarter in the previous year.
Its net income has increased by 16.2% to $-46M since the same quarter in the previous year.
Finally, its free cash flow grew by 174.6% to $22M since the same quarter in the previous year.
Based on the above factors, Aerie Pharmaceuticals, Inc gets an overall score of 5/5.